28-Mar-2024
No headlines found.
Globe Newswire (Thu, 14-Mar 8:30 AM ET)
MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
Globe Newswire (Tue, 13-Feb 8:00 AM ET)
PRNewswire (Thu, 1-Feb 7:30 AM ET)
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Meiragtx Hldgs trades on the NASDAQ stock market under the symbol MGTX.
As of March 28, 2024, MGTX stock price declined to $6.07 with 171,170 million shares trading.
MGTX has a beta of 2.77, meaning it tends to be more sensitive to market movements. MGTX has a correlation of 0.14 to the broad based SPY ETF.
MGTX has a market cap of $389.80 million. This is considered a Small Cap stock.
Last quarter Meiragtx Hldgs reported $2 million in Revenue and $.42 earnings per share. This fell short of revenue expectation by $-5 million and exceeded earnings estimates by $.53.
In the last 3 years, MGTX stock traded as high as $24.89 and as low as $3.49.
The top ETF exchange traded funds that MGTX belongs to (by Net Assets): IWM, IBB, IWO, VHT, VTWO.
MGTX has underperformed the market in the last year with a price return of +18.6% while the SPY ETF gained +33.6%. MGTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -14.6% and -4.4%, respectively, while the SPY returned +10.1% and +1.7%, respectively.
MGTX support price is $5.96 and resistance is $6.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MGTX stock will trade within this expected range on the day.